Clinical Trials Browser

inavolisib × Breast × Clear all

NCT07543250 2026-04-21

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Not yet recruiting

Breast Neoplasms

NCT07347600 2026-04-20

reaINAVO

Breast Neoplasms

NCT07405801 2026-04-20

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07368998 2026-04-13

optINAVO

Phase 2 Recruiting

Breast Neoplasms

NCT06790693 2026-04-03

INAVO123

Phase 3 Recruiting

Breast Neoplasms

NCT05894239 2026-03-31

INAVO122

Phase 3 Recruiting

Breast Neoplasms

NCT07054190 2026-03-31

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 2 FDA

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT05708235 2026-03-05

MiRaDoR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT05646862 2026-02-05

INAVO121

Phase 3 Active not recruiting

Breast Neoplasms

NCT07245797 2025-11-24

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Phase 2 Recruiting

Breast Neoplasms

NCT05306041 2025-02-17

GeparPiPPa

Phase 2 Recruiting

HER2-positive Breast Cancer